Leerink initiated coverage of Contineum (CTNM) with an Outperform rating and $20 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Promising Potential of PIPE-791: Buy Rating for Contineum Therapeutics Amid Positive Phase 1b Results
- Buy Rating for Contineum Therapeutics’ PIPE-791: Promising Phase 1b Results and Competitive Edge
- Contineum announces topline data from PIPE-791 trial
- Contineum Therapeutics Announces Positive Phase 1b Trial Results
- 3 Best Stocks to Buy Now, 8/19/2025, According to Top Analysts